Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/10/2005Meridian Bioscience Reports Record Fiscal 2005 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI, Nov 10, 2005 (BUSINESS WIRE) -- GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record fiscal 2005 net sales of $93 million and record diluted earnings per share of $0.52, respective increases of 17% and 30% over the prior fiscal year; reported fourth quarter fiscal 2005 net sales of $25 million and diluted earnings per share of $0.15, respective increases of 12% and 15% over the same period ... 
 Printer Friendly Version
10/31/2005Meridian Bioscience Again Recognized by Forbes as One of The 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 31, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the third year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consist... 
 Printer Friendly Version
10/18/2005Meridian Bioscience H. Pylori Patent Upheld by European Patent Office
CINCINNATI--(BUSINESS WIRE)--Oct. 18, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its patent entitled "Immunoassay for Helicobacter pylori in Fecal Specimens" has been confirmed as valid by the European Patent Office. The validity of the Patent had been challenged in four Oppositions filed by a total of seven parties. The objections raised were that the Patent added subject matter to the Application as originally filed, lacked novelty, lacked inventive steps an... 
 Printer Friendly Version
9/23/2005Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2005--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Sciences Conference, Tuesday, September 27, 2005 at 12:00 p.m. ET at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present. A question and answer session will follow and some of the information provided during the session may not have bee... 
 Printer Friendly Version
9/16/2005Meridian Bioscience Announces Pricing of $58 Million Common Stock Offering
CINCINNATI, Sep 16, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has priced a public offering of 3,300,000 shares of common stock at $17.50 per share. Of the total number of shares, 1,800,000 shares are being offered by the Company, and 1,500,000 shares are being offered by The William J. Motto Irrevocable Family Trust. Mr. Motto is the Company's Chairman and Chief Executive Officer. The shares are being offered pursuant to a sh... 
 Printer Friendly Version
8/15/2005Meridian Bioscience Announces 3-for-2 Stock Split and Provides Sales and Earnings Guidance for Fiscal 2006
CINCINNATI--(BUSINESS WIRE)--Aug. 15, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its Board of Directors has declared a three-for-two stock split of the Company's common shares. The record date is August 29, 2005 with the payment date set for September 2, 2005. Cash will be paid in lieu of fractional shares. Management also today provided the financial community with guidance regarding the Company's fiscal 2006 sales and earnings estimates. ... 
 Printer Friendly Version
7/21/2005Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Higher Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--July 21, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record third quarter sales of $25,421,000, a 39% increase over the same period of the prior fiscal year and an all-time record for any quarter in the Company's history; reported record third quarter operating income of $5,708,000, an increase of 70% over the same period of the prior fiscal year and an all-time record for any qu... 
 Printer Friendly Version
7/11/2005Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--July 11, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2005 earnings from a range of $0.66 to $0.70 per share to a new range of $0.73 to $0.76 per share. The per share estimates assume an increase in average shares outstanding from approximately 15.3 million at fiscal 2004 year end to 16.1 million at fiscal 2005 year end. Due to stronger than expected third quarter shipments, net sales guidance... 
 Printer Friendly Version
7/7/2005Meridian Bioscience Awarded Exclusive, Global License for Parvovirus B19 Vaccine from the National Institutes of Health
CINCINNATI, Jul 07, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), Memphis, TN, was awarded the exclusive global license for the recombinant Parvovirus B19 Vaccine technology from the National Institutes of Health (NIH). The license provides VAI with the exclusive and global rights to utilize the NIH's patented technology to develop, manufacture, and market the Parvovirus B19 vaccine. Previo... 
 Printer Friendly Version
7/6/2005Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI, Jul 06, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2005. This index is made up of 314 stocks composed of U.S. companies with the most consistent records of annual dividend increases. Quoting from Mergent's press release, "Dividend Achievers represent the elite of the U.S. stock market. These are generally well known companies that as a group have been... 
 Printer Friendly Version
6/22/2005New Meridian Bioscience Patent Improves Rubella Testing Accuracy
CINCINNATI--(BUSINESS WIRE)--June 22, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that Viral Antigens, Inc. (VAI), a wholly owned life science subsidiary, received a patent entitled "Specificity in the Detection of Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark Office. This patent encompasses improved methods for detection of anti-rubella IgM antibodies in commercial diagnostic products, utilized to test blood samples for the presence o... 
 Printer Friendly Version
6/20/2005Fortune Small Business Ranks Meridian Bioscience Among America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--June 20, 2005--(NASDAQ:VIVO) - FORTUNE Small Business announced today that Meridian Bioscience, Inc., has been ranked 80 on the fifth annual FSB 100 list of the 100 fastest growing small companies in America. The list, which is comprised of public companies, appears in the July/August issue of FORTUNE Small Business, available on newsstands July 4 and at www.fsb.com. John A. Kraeutler, President and Chief Operating Officer, stated, "This recognition by F... 
 Printer Friendly Version
6/14/2005Meridian Bioscience Announces Final Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI, Jun 14, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has called for redemption on July 8, 2005, all of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. At June 10, 2005, there were approximately $1.8 million of principal amount of such debentures outstanding. On or prior to the close of business on July 7, 2005, holders of the 7% Convertible Debentures be... 
 Printer Friendly Version
6/1/2005Meridian Bioscience Recognized as One of the 100 Best Small Companies of 2005 by Business Week Magazine
CINCINNATI--(BUSINESS WIRE)--June 1, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been recognized by Business Week magazine as one of "The 100 Best Small Companies." The 100 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $50 million and $1.5 billion. Additional qualification criteria included rankings based upon sales... 
 Printer Friendly Version
5/10/2005Meridian Bioscience to Present at the Robert W. Baird 2005 Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--May 10, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2005 Growth Stock Conference on Wednesday, May 11, 2005 at 2:05 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow and some of the infor... 
 Printer Friendly Version
5/9/2005Meridian Bioscience Announces Third Partial Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--May 9, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has called for redemption on June 3, 2005, $2.5 million in principal amount of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. The called 7% Convertible Debentures will be selected in accordance with the applicable procedures of the Trustee, U.S. Bank, National Association, for partial redemption. Holders of 7% Convertible D... 
 Printer Friendly Version
4/21/2005Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--April 21, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported all-time record quarterly sales of $23,686,000, a 13% increase over the same period of the prior fiscal year and an all-time record for any quarter in the Company's history; reported all-time record quarterly operating income of $5,198,000, an increase of 31% over the same period of the prior fiscal year and an all-time recor... 
 Printer Friendly Version
4/13/2005Meridian Bioscience Announces Preliminary Operating Results for the Second Quarter, Reaffirms Guidance, and Comments on Recommended Destruction of Influenza A Samples
CINCINNATI--(BUSINESS WIRE)--April 13, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that, based on preliminary results, it expects to report net sales of approximately $23.5 million and diluted earnings per share of between $0.19 and $0.20 for the quarter ended March 31, 2005. For the same period of the previous fiscal year, sales and diluted earnings per share were $20.94 million and $0.15, respectively. The Company will report its final results for the fiscal second qu... 
 Printer Friendly Version
3/16/2005Meridian Bioscience Expands Presence in Veterinary Market and Announces Agreement with Synbiotics Corporation
CINCINNATI--(BUSINESS WIRE)--March 16, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a Distribution Agreement with Synbiotics Corporation for the distribution of VAI's veterinary products through Synbiotics' global sales, marketing, and distribution channels. Synbiotics develops, manufactures, and markets veterinary diagnostic products for the animal health market and is seeking to broaden its ... 
 Printer Friendly Version
3/1/2005Meridian Bioscience to Present at Friedman, Billings, Ramsey & Co. 2005 Washington Conference
CINCINNATI, Mar 1, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Friedman, Billings, Ramsey & Co. 2005 Washington Conference on Thursday, March 3, 2005 at 2:20 p.m. EST at the Mandarin Oriental Washington in Washington, D.C. The Conference will feature presentations from companies representing Homeland Security, Defense and Government IT. Jack Kraeutler, President and Chief Operating Of... 
 Printer Friendly Version
2/9/2005Meridian Bioscience Targets Biodefense Market by Providing Contract Services for BEI Resources
CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI) has entered the emerging biodefense market by providing contract services for Biodefense and Emerging Infections (BEI) Resources. BEI Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to acquire, authenticate, and produce reage... 
 Printer Friendly Version
2/1/2005Meridian Bioscience Completes Acquisition of O.E.M. Concepts and Comments on New Growth Opportunities
CINCINNATI--(BUSINESS WIRE)--Feb. 1, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has completed the purchase of O.E.M. Concepts, Inc., highlights include: purchase price of $6.0 million in cash and a performance based earnout opportunity of $2.3 million over a four-year period, as previously reported; earnings accretion of between $0.01 and $0.02 for the balance of fiscal 2005 and $0.04 to $0.06 for fiscal 2006 ... 
 Printer Friendly Version
1/20/2005Meridian Bioscience Reports Record First Quarter Operating Results, Executes Agreement To Buy O.E.M. Concepts, Declares Higher Dividend, and Reaffirms Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 20, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record first quarter net sales of $18,842,000, a 4% increase over the same period of the prior fiscal year; reported record first quarter net earnings of $2,110,000, an 18% increase over the same period of the prior fiscal year; reported record first quarter dilu... 
 Printer Friendly Version
1/18/2005Meridian Bioscience Reports Completion of 7% Convertible Debentures Redemption
CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its call for the redemption of $4.0 million in principal amount of its outstanding 7% Convertible Subordinated Debentures Due September 1, 2006, was successfully completed on January 14, 2005, as planned. The result of the redemption call was that $3.4 million was converted into 211,000 shares of the Company's underlying common stock and $603,000 was redeemed at par v... 
 Printer Friendly Version